TY - JOUR T1 - Primary and additional treatment preference in aggressive retinopathy of prematurity and type 1 retinopathy of prematurity JF - BMJ Open Ophthalmology JO - BMJ Open Ophth DO - 10.1136/bmjophth-2022-001166 VL - 8 IS - 1 SP - e001166 AU - Ji Hye Jang AU - Yong Koo Kang AU - Han Sang Park AU - Kiyoung Kim AU - Sung Soo Kim AU - Jae Yong Han AU - Hyun Wong Kim AU - Jong Wook Bang AU - Jae Shin Song AU - Sang Jun Park AU - Se Joon Woo AU - Kwang Sic Joo AU - Woong-Sun Yoo AU - Inyoung Chung AU - Yong-Wun Cho AU - Jong Hyun Lee AU - Hun Jin Choi AU - Yoo-Ri Chung Y1 - 2023/01/01 UR - http://bmjophth.bmj.com/content/8/1/e001166.abstract N2 - Objective This study aimed to evaluate the preference for antivascular endothelial growth factor (anti-VEGF) versus laser ablation therapy as primary and additional treatment in aggressive retinopathy of prematurity (ROP) and type 1 ROP.Methods This multicentre retrospective study was conducted at nine medical centres across South Korea. A total of 94 preterm infants with ROP who underwent primary treatment between January 2020 and December 2021 were enrolled. All eyes were classified as having type 1 ROP or aggressive ROP. Data on the zone, primary treatment chosen, injection dose, presence of reactivation and additional treatment were collected and analysed.Results Seventy infants (131 eyes) with type 1 ROP and 24 infants (45 eyes) with aggressive ROP were included. Anti-VEGF injection was selected as the primary treatment in 74.05% of the infants with type 1 ROP and 88.89% with aggressive ROP. Anti-VEGF injection was selected as the ROP was located in zone I or posterior zone II, and laser ablation was selected when it was located in zone II. The anti-VEGF injection doses varied and tended to be higher in the aggressive ROP group. Infants with aggressive ROP were 2.08 times more likely to require additional treatment than those with type 1 ROP. When ROP reactivation occurred, laser therapy was preferred as an additional treatment.Conclusion In Korea, the preference for anti-VEGF therapy or laser therapy differed according to ROP subtype, zone and primary or secondary treatment. These findings suggest that ROP treatment are considered according to ROP subtype, location and reactivation.Data are available on reasonable request. ER -